We began the analysis of circulating MACC1 levels with respect to the survival of newly diagnosed CRC patients with a primary tumor with or without synchronous metastases (blood samples were taken at the day of diagnosis) (Fig. 3A). This evidence concerns the gene MACC1 and colorectal carcinoma.